ACURA PHARMACEUTICALS INC
Acura Pharmaceuticals develops technologies and products for safe medication use. They offer Oxaydo tablets for pain management and Nexafed products for nasal decongestants. The company collaborates with Egalet to manufacture and commercialize Oxaydo worldwide. Acura also has an agreement with Abuse Deterrent Pharma to develop LTX-03, a LIMITx technology tablet.
Overview
Strengths
- Price to book ratio (0.18) is lower than the sector mean (733.70).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (14.71%).
- EV/EBITDA (100.00) is significantly higher than the sector mean (51.86).
- The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |